Exiqon Awarded Global microRNA Research Tools Company of the Year
News Jul 08, 2013
This award follows Frost & Sullivan's most recent analysis of the global microRNA research tools and services market.
Exiqon was one of the first companies to commercially serve the microRNA market and scientists around the world have published thousands of peer-reviewed scientific papers based on Exiqon’s microRNA research products since the first product introductions in 2005.
Most recently, Exiqon has developed a database search tool, miRSearch, which allows customers to do simple and intuitive searches across a dozen relevant databases and easily navigate the overwhelming amount of microRNA information when designing experiments. The search tool is accessible at www.exiqon.com/mirsearch. This recent extension complements Exiqon’s leading miRCURY LNA™ products for microRNA research that include validated microRNA products for sample extraction, gene expression and functional analysis, as well as advanced software for data analysis.
Exiqon has been cited as a preferred one-stop shop provider of complete workflow solutions pertaining to microRNA research. Provision of microRNA profiling and screening services along with products has not only simplified purchasing, but has also attracted new customers for Exiqon.
“Over the past eight years, the microRNA research space has evolved from an exotic research field to an emerging market which includes validated biomarkers and clinical applications,” says Exiqon CEO Lars Kongsbak. “According to Frost & Sullivan analysis, Exiqon holds an average market share of 24 percent, thereby continuing to be instrumental in helping scientists across industry and academia understand and apply the biology of microRNAs”.
Children who are genetically predisposed to overweight, due to common gene variants, can still lose weight by changing their diet and exercise habits. Around 750 children and adolescents with overweight or obesity undergoing lifestyle intervention participated in the study conducted by researchers from the University of Copenhagen and Holbæk Hospital.